Found 8 results
Author Title [ Type(Desc)] Year
Filters: Author is Ho, Vincent T  [Clear All Filters]
Journal Article
J. E. Levine, Logan, B. R., Wu, J., Alousi, A. M., Bolaños-Meade, J., Ferrara, J. L. M., Ho, V. T., Weisdorf, D. J., and Paczesny, S., Acute graft-versus-host disease biomarkers measured during therapy can predict treatment outcomes: a Blood and Marrow Transplant Clinical Trials Network study., Blood, vol. 119, no. 16, pp. 3854-60, 2012.
V. T. Ho, Cutler, C., Carter, S., Martin, P., Adams, R., Horowitz, M., Ferrara, J., Soiffer, R., and Giralt, S., Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation., Biol Blood Marrow Transplant, vol. 11, no. 8, pp. 571-5, 2005.
A. M. Alousi, Weisdorf, D. J., Logan, B. R., Bolaños-Meade, J., Carter, S., DiFronzo, N., Pasquini, M., Goldstein, S. C., Ho, V. T., Hayes-Lattin, B., Wingard, J. R., Horowitz, M. M., and Levine, J. E., Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network., Blood, vol. 114, no. 3, pp. 511-7, 2009.
J. Bolaños-Meade, Wu, J., Logan, B. R., Levine, J. E., Ho, V. T., Alousi, A. M., Weisdorf, D. J., and Luznik, L., Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302., Biol Blood Marrow Transplant, vol. 19, no. 3, pp. 481-5, 2013.
J. Bolaños-Meade, Logan, B. R., Alousi, A. M., Antin, J. H., Barowski, K., Carter, S. L., Goldstein, S. C., Hexner, E. O., Horowitz, M. M., Lee, S. J., Levine, J. E., MacMillan, M. L., Martin, P. J., Mendizabal, A. M., Nakamura, R., Pasquini, M. C., Weisdorf, D. J., Westervelt, P., and Ho, V. T., Phase 3 clinical trial of steroids/mycophenolate mofetil vs steroids/placebo as therapy for acute GVHD: BMT CTN 0802., Blood, vol. 124, no. 22, pp. 3221-7; quiz 3335, 2014.
K. Ballen, Mendizabal, A. M., Cutler, C., Politikos, I., Jamieson, K., Shpall, E. J., Dey, B. R., Attar, E., McAfee, S., Delaney, C., McCarthy, P., Ball, E. D., Kamble, R., Avigan, D., Maziarz, R. T., Ho, V. T., Koreth, J., Alyea, E., Soiffer, R., Wingard, J. R., Boussiotis, V., Spitzer, T. R., and Antin, J. H., Phase II trial of parathyroid hormone after double umbilical cord blood transplantation., Biol Blood Marrow Transplant, vol. 18, no. 12, pp. 1851-8, 2012.
G. A. Yanik, Horowitz, M. M., Weisdorf, D. J., Logan, B. R., Ho, V. T., Soiffer, R. J., Carter, S. L., Wu, J., Wingard, J. R., Difronzo, N. L., Ferrara, J. L., Giralt, S., Madtes, D. K., Drexler, R., White, E. S., and Cooke, K. R., Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials ne, Biol Blood Marrow Transplant, vol. 20, no. 6, pp. 858-64, 2014.
C. Cutler, Stevenson, K., Kim, H. T., Richardson, P., Ho, V. T., Linden, E., Revta, C., Ebert, R., Warren, D., Choi, S., Koreth, J., Armand, P., Alyea, E., Carter, S., Horowitz, M., Antin, J. H., and Soiffer, R., Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation., Blood, vol. 112, no. 12, pp. 4425-31, 2008.